Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ non-Hodgkin
lymphoma. Anaplastic lymphoma kinase–positive (ALK+) ALCL is associated with the NPM …

Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a large-cell neoplasm
with anaplastic morphology immunostained by the Ki-1 antibody, which recognizes CD30. In …

Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL),
remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy …

Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell
lymphoproliferations that share morphological and immunophenotypical features, namely …

Background Non‐Hodgkin lymphoma (NHL) is a relatively common malignancy in pediatric
patients; however, a small subgroup have unusual lymphoma subtypes for the pediatric …

Simple Summary Primary anaplastic large cell lymphoma (ALCL) of the central nervous
system (CNS) is a subtype of primary central nervous system lymphoma (PCNSL). ALCL is …

Objectives Primary central nervous system anaplastic large cell lymphoma, anaplastic
lymphoma kinase positive (primary CNS ALCL, ALK+) is a rare CNS lymphoma whose …

Background Central nervous system (CNS) lymphomas frequently pose a diagnostic
challenge to physicians. CNS anaplastic large cell lymphoma (ALCL) is a rare condition. A …

Background Histone acetyltransferase (HAT) inhibitors can inhibit proliferation and induce
apoptosis in cancer cell lines. The novel cell-permeable p300/CREB-binding protein (CBP) …

Purpose: To review the existing literature on patients with anaplastic large cell lymphoma
(ALCL) affecting the globe and/or ocular adnexa, and to present a report documenting the …